Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells

Cancer Letters

Volumn 337, Issue 2, 2013, Pages 177-183

  Gulappa, Thippeswamy ^a   Reddy, Ramadevi Subramani ^a   Suman, Suman ^a   Nyakeriga, Alice M ^a   Damodaran, Chendil ^a  

^a USA   (United States)

Author keywords

Castration resistant prostate cancer; Cell cycle arrest; Cyclin dependent kinase; Cyclins; Growth inhibition

Indexed keywords

3,9 DIHYDROXY 2 PRENYLCOUMESTAN; ANTIMITOTIC AGENT; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION;

CASTRATION-RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CYCLIN-DEPENDENT KINASE; CYCLINS; GROWTH INHIBITION;

CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; E2F1 TRANSCRIPTION FACTOR; G0 PHASE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PSORALENS; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84880513913     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.014     Document Type: Article

References (46)

1. Aggarwal R., Ryan C.J. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist 2011, 16:264-275.
2. Amaral T.M., Macedo D., Fernandes I., Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate cancer 2012, 2012:327253.
3. Benci K., Mandic L., Suhina T., Sedic M., Klobucar M., Kraljevic Pavelic S., Pavelic K., Wittine K., Mintas M. Novel coumarin derivatives containing 1,2,4-triazole, 4,5-dicyanoimidazole and purine moieties: synthesis and evaluation of their cytostatic activity. Molecules 2012, 17:11010-11025.
4. Berthet C., Klarmann K.D., Hilton M.B., Suh H.C., Keller J.R., Kiyokawa H., Kaldis P. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev. Cell 2006, 10:563-573.
5. Besson A., Gurian-West M., Chen X., Kelly-Spratt K.S., Kemp C.J., Roberts J.M. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006, 20:47-64.
6. Bloom J., Cross F.R. Multiple levels of cyclin specificity in cell-cycle control. Nat. Rev. Mol. Cell Biol. 2007, 8:149-160.
7. Bronikowska J., Szliszka E., Jaworska D., Czuba Z.P., Krol W. The coumarin psoralidin enhances anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Molecules 2012, 17:6449-6464.
8. Cmielova J., Rezacova M. P21Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J. Cell Biochem. 2011, 112:3502-3506.
9. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol. 2003, 13:65-70.
10. Deep G., Agarwal R. New combination therapies with cell-cycle agents. Curr. Opin. Invest. Drugs 2008, 9:591-604.
11. Denicourt C., Dowdy S.F. Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev. 2004, 18:851-855.
12. Dickson M.A., Schwartz G.K. Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 2009, 16:36-43.
13. George D., Moul J.W. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate 2012, 72:338-349.
14. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68:67-108.
15. Hallstrom T.C., Nevins J.R. Balancing the decision of cell proliferation and cell fate. Cell Cycle 2009, 8:532-535.
16. Hastak K., Agarwal M.K., Mukhtar H., Agarwal M.L. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005, 19:789-791.
17. Henley S.A., Dick F.A. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div. 2012, 7:10.
18. Higano C.S., Crawford E.D. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol 2011, 29:S1-8.
19. Ho E., Beaver L.M., Williams D.E., Dashwood R.H. Dietary factors and epigenetic regulation for prostate cancer prevention. Adv. Nutr 2011, 2:497-510.
20. Hong W.K., Sporn M.B. Recent advances in chemoprevention of cancer. Science 1997, 278:1073-1077.
21. Jiang Y., Zhao R.C., Verfaillie C.M. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc. Natl. Acad. Sci. USA 2000, 97:10538-10543.
22. Joshi I., Minter L.M., Telfer J., Demarest R.M., Capobianco A.J., Aster J.C., Sicinski P., Fauq A., Golde T.E., Osborne B.A. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood 2009, 113:1689-1698.
23. Kontogiorgis C., Detsi A., Hadjipavlou-Litina D. Coumarin-based drugs: a patent review (2008-present). Expert Opin. Ther. Pat. 2008, 22(2012):437-454.
24. Kucuk O. Chemoprevention of prostate cancer. Cancer Metastasis Rev. 2002, 21:111-124.
25. Kumar R., Srinivasan S., Pahari P., Rohr J., Damodaran C. Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol. Cancer. Ther. 2010, 9:2488-2496.
26. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., Lee J.H., Ciarallo S., Catzavelos C., Beniston R., Franssen E., Slingerland J.M. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 2002, 8:1153-1160.
27. Lim D.Y., Tyner A.L., Park J.B., Lee J.Y., Choi Y.H., Park J.H. Inhibition of colon cancer cell proliferation by the dietary compound conjugated linoleic acid is mediated by the CDK inhibitor p21CIP1/WAF1. J. Cell Physiol. 2005, 205:107-113.
28. Mols F., Korfage I.J., Vingerhoets A.J., Kil P.J., Coebergh J.W., Essink-Bot M.L., van de Poll-Franse L.V. Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73:30-38.
29. Pan M.H., Ghai G., Ho C.T. Food bioactives, apoptosis, and cancer. Mol. Nutr. Food Res. 2008, 52:43-52.
30. Pan M.H., Ho C.T. Chemopreventive effects of natural dietary compounds on cancer development. Chem. Soc. Rev. 2008, 37:2558-2574.
31. Riveiro M.E., De Kimpe N., Moglioni A., Vazquez R., Monczor F., Shayo C., Davio C. Coumarins: old compounds with novel promising therapeutic perspectives. Curr. Med. Chem. 2010, 17:1325-1338.
32. Sandal T. Molecular aspects of the mammalian cell cycle and cancer. Oncologist 2002, 7:73-81.
33. Shimizu-Sato S., Ike Y., Mori H. PsRBR1 encodes a pea retinoblastoma-related protein that is phosphorylated in axillary buds during dormancy-to-growth transition. Plant Mol. Biol. 2008, 66:125-135.
34. Shore N., Mason M., de Reijke T.M. New developments in castrate-resistant prostate cancer. BJU Int. 2012, 109(Suppl 6):22-32.
35. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62(2012):10-29.
36. Simile M.M., De Miglio M.R., Muroni M.R., Frau M., Asara G., Serra S., Muntoni M.D., Seddaiu M.A., Daino L., Feo F., Pascale R.M. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 2004, 25:333-341.
37. Singh S., Johnson J., Chellappan S. Small molecule regulators of Rb-E2F pathway as modulators of transcription. Biochim. Biophys. Acta 2010, 1799:788-794.
38. Srinivasan S., Kumar R., Koduru S., Chandramouli A., Damodaran C. Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer. Apoptosis 2010, 15:153-161.
39. Szliszka E., Czuba Z.P., Sedek L., Paradysz A., Krol W. Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacol. Rep. 2011, 63:139-148.
40. Vermeulen K., Van Bockstaele D.R., Berneman Z.N. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36:131-149.
41. Viallard J.F., Lacombe F., Belloc F., Pellegrin J.L., Reiffers J. Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology. Cancer Radiother. 2001, 5:109-129.
42. Xiao G., Li G., Chen L., Zhang Z., Yin J.J., Wu T., Cheng Z., Wei X., Wang Z. Isolation of antioxidants from Psoralea corylifolia fruits using high-speed counter-current chromatography guided by thin layer chromatography-antioxidant autographic assay. J. Chromatogr. A 2010, 1217:5470-5476.
43. Yang H.J., Youn H., Seong K.M., Yun Y.J., Kim W., Kim Y.H., Lee J.Y., Kim C.S., Jin Y.W., Youn B. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation. Biochem. Pharmacol. 2011, 82:524-534.
44. Yang Y.M., Hyun J.W., Sung M.S., Chung H.S., Kim B.K., Paik W.H., Kang S.S., Park J.G. The cytotoxicity of psoralidin from Psoralea corylifolia. Planta. Med. 1996, 62:353-354.
45. Yaroslavskiy B., Watkins S., Donnenberg A.D., Patton T.J., Steinman R.A. Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells. Blood 1999, 93:2907-2917.
46. T.P. Das, S. Suman, C. Damodaran, Reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells, Molecular carcinogenesis, (2013). http://dx.doi.org/10.1002/mc.22014.